Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
暂无分享,去创建一个
J. Jassem | R. C. Coombes | G. Bertelli | E. Hall | J. Bliss | E. Ireland | K. Drosik | C. Snowdon | H. Karnicka-Młodkowska | E. Hall | R. Coombes
[1] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[2] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.
[3] F. Grossi,et al. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer. , 2007, European journal of obstetrics, gynecology, and reproductive biology.
[4] P. Lønning,et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.
[5] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Cawthorn,et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.
[7] G. Garuti,et al. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. , 2006, Gynecologic oncology.
[8] R. Coombes,et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Kundt,et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. , 2006, Obstetrics and gynecology.
[11] I. Cohen,et al. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients , 2006, Breast Cancer Research and Treatment.
[12] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[13] A. Paredes,et al. Endometrial thickness of postmenopausal breast cancer patients treatedwith tamoxifen , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[14] F. Machado,et al. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. , 2005, European journal of gynaecological oncology.
[15] A. Bianco,et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. , 2005, Human reproduction.
[16] D. Timmerman,et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] C. Davies. Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen. , 2004, Cancer treatment reviews.
[18] I. Cohen. Endometrial pathologies associated with postmenopausal tamoxifen treatment. , 2004, Gynecologic oncology.
[19] P. Lønning,et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.
[20] N. Ragni,et al. Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. , 2004, European journal of gynaecological oncology.
[21] O. Garrone,et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination , 2004, Breast Cancer Research and Treatment.
[22] P. Lønning,et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Figer,et al. Ultrasonographic Measurement of Endometrial Changes following Discontinuation of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients , 2000, BJOG : an international journal of obstetrics and gynaecology.
[24] J. Magaziner,et al. Surveillance for uterine abnormalities in tamoxifen‐treated breast carcinoma survivors , 2000, Cancer.
[25] J. Dixon,et al. Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. , 2000, Breast.
[26] A. Steiner. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. , 1999, Obstetrics and gynecology.
[27] B. Muir,et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. V. D. Van Der Zee,et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. , 1999, Gynecologic oncology.
[29] J Scheidler,et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. , 1998, JAMA.
[30] D. Taylor,et al. Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen. , 1998, Climacteric : the journal of the International Menopause Society.
[31] P. Lønning,et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] P. Neven,et al. Should tamoxifen users be screened for endometrial lesions? , 1998, The Lancet.
[33] P. Sismondi,et al. Tamoxifen and Endometrial Cancer , 1994, Annals of the New York Academy of Sciences.
[34] J. Bornstein,et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. , 1994, The Journal of reproductive medicine.
[35] I. Cohen,et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. , 1994, Gynecologic oncology.
[36] A. Kauppila,et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. , 1993, Obstetrics and gynecology.